8-Bromoimidazo[1,2-a]pyrazine
97%
- Product Code: 146631
CAS:
69214-34-2
| Molecular Weight: | 198.02 g./mol | Molecular Formula: | C₆H₄BrN₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C |
Product Description:
Used in pharmaceutical research as a key intermediate in the synthesis of biologically active compounds, particularly kinase inhibitors. Shows potential in the development of anti-inflammatory and anticancer agents due to its ability to modulate signaling pathways. Also employed in the design of novel neuroprotective drugs targeting central nervous system disorders. Its bromo functional group allows for further derivatization via cross-coupling reactions, making it valuable in medicinal chemistry for structure-activity relationship studies.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 0.100 | 10-20 days | ฿790.00 |
+
-
|
| 1.000 | 10-20 days | ฿6,770.00 |
+
-
|
8-Bromoimidazo[1,2-a]pyrazine
Used in pharmaceutical research as a key intermediate in the synthesis of biologically active compounds, particularly kinase inhibitors. Shows potential in the development of anti-inflammatory and anticancer agents due to its ability to modulate signaling pathways. Also employed in the design of novel neuroprotective drugs targeting central nervous system disorders. Its bromo functional group allows for further derivatization via cross-coupling reactions, making it valuable in medicinal chemistry for structure-activity relationship studies.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :